☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Regulatory
Amolyt Pharma’s Eneboparatide Receives the US FDA’s Fast Track Designation for Hypoparathyroidism
May 3, 2024
Taysha Gene Therapies’ TSHA-102 Receives the US FDA’s Regenerative Medicine Advanced Therapy Designation for Rett Syndrome
May 3, 2024
New Drug Designations - March 2024
April 30, 2024
X4 Pharmaceuticals’ Xolremdi Receives the US FDA’s Approval for the Treatment of WHIM Syndrome
April 30, 2024
Johnson & Johnson’s Sirturo Gains the CHMP’s Positive Opinion to Treat Multidrug-Resistant Tuberculosis
April 30, 2024
AstraZeneca’s Truqap Plus Faslodex Receives the CHMP’s Positive Opinion for Treating Breast Cancer
April 29, 2024
Load more...
Back to Home